Biography:

Dr. Suh-Chin Wu is Professor of Institute of Biotechnology, Department of Medical Science at National Tsing Hua University, Hsinchu, Taiwan. He is also the Adjunct Investigator of National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan. Dr. Wu received his Ph.D. in Chemical Engineering from Texas A&M University, completed his postdoctoral training at National Institute of Health, US. He first joined the vaccine group at Taiwanese Center for Disease Control as Associate Investigator and then the Department of Life Science at National Tsing Hua University. He has participated in the Taiwanese CDC/NHRI vaccine group(s) in the developments of inactivated cell culture vaccines for Japanese encephalitis, enterovirus type 71, H5N1, and pH1N1 viruses. His current works are focused on the novel antigen and adjuvant design for inducing more potent neutralizing antibodies, mucosal IgA antibodies, and Th17 cellular response against virus infections. For human and avian influenza vaccine research, the rationale design for “glycan-masking” and "glycan-unmasking" HA antigens is used to elicit more broadly neutralizing antibodies by refocusing the antibody responses to the more conserved regions. Another approach is to dissect the cross-reactive epitopes on the NA antigens for inducing more cross-reactive NA inhibiting antibodies that may also improve vaccine protection or the outcome of disease severity. For dengue and Zika vaccine research, his works include the use of infectious clone technology to construct mutant viruses for developing live-attenuated vaccines. He has authored over 80 scientific papers and 10 patents related to human vaccine and biologics development. He has also co-founded the Taiwan Chapter of Regulatory Affairs Professionals Society (RAPS) for promoting international education in regulatory sciences for biologics and vaccines, and he currently is the chairman of RAPS Taiwan Chapter.

Research Interests:

His current works are focused on the novel antigen and adjuvant design for inducing more potent neutralizing antibodies, mucosal IgA antibodies, and Th17 cellular response against virus infections.